Full history for every metric is available with a Kvantra account
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHF m | 4,508 | 5,409 | 6,223 | 6,717 | 5,480 | 6,531 | 6,329 | 7,117 |
| Operating profit | CHF m | 1,382 | 1,555 | ||||||
| Net profit | CHF m | 869 | 2,944 | 1,215 | 654 | 636 | -275 | -110 | 1,297 |
| EPS reported | CHF | -3.93 | -1.55 | ||||||
| Operating cashflow per share | CHF | 16.69 | 20.66 | ||||||
| Capex per share | CHF | 19.61 | 18.33 | ||||||
| FCF per share | CHF | -2.91 | 2.33 | ||||||
| Free cash flow | CHF m | -204 | 163 | ||||||
| Net debt | CHF m | 3,466 | 3,680 | ||||||
| Book value equity | CHF m | 9,134 | 8,120 | ||||||
| Book value per share | CHF | 130.4 | 116.1 | ||||||
| Number of shares | m | 70.02 | 69.94 | ||||||
| DPS (TTM paid) | CHF | 5.00 | 5.00 |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.12 | 4.87 | ||||||
| P/S LTM | x | 5.77 | 6.24 | ||||||
| P/FCF LTM | x | -184.60 | 242.36 | ||||||
| EV/EBITDA LTM | x | 20.45 | 20.06 | ||||||
| EV/Sales LTM | x | 6.35 | 6.82 | ||||||
| Earnings Yield LTM | % | -0.73% | -0.28% | ||||||
| FCF Yield | % | -0.54% | 0.41% | ||||||
| Quality | |||||||||
| ROE | % | -3.01% | -1.28% | ||||||
| ROIC | % | 7.27% | 8.60% | ||||||
| Operating margin | % | 21.16% | 24.57% | ||||||
| Gross margin | % | 35.25% | 36.53% | ||||||
| FCF/Sales | % | -3.12% | 2.58% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +19.18% | -3.39% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +26.56% | +43.19% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.74% | 0.88% | ||||||
| Dividend Growth | % | +25.00% | +25.00% | ||||||
| Payout Ratio | % | -101.75% | -101.82% | ||||||
| FCF/Debt | x | -0.04 | 0.04 | ||||||
| Net Debt/EBITDA | x | 1.88 | 1.71 | ||||||
| EBIT/Net interest | x | 8.28 | 13.18 | ||||||
| Net debt/market cap | % | 9.20% | 9.32% | ||||||
| Net debt/Equity | x | 0.38 | 0.45 | ||||||
| Gross debt/equity | x | 0.50 | 0.51 | ||||||
ETFs that hold Lonza Group
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Core SPI(R) ETF (CH) | CHSPI.SW | 9 | 2.19% |
| iShares SMI ETF (CH) | CSSMI.SW | 9 | 2.77% |
| UBS ETF (CH) – SMI | SMICHA.SW | 9 | 2.64% |
| Xtrackers Switzerland UCITS ETF 1C | XSMC.SW | 9 | 2.77% |
| iShares MSCI Switzerland ETF | EWL | 8 | 2.84% |
| Amundi MSCI Europe SRI Climate Paris Aligned UCITS ETF DR (C) | MIVB.DE | 10 | 2.14% |
| iShares MSCI Europe Health Care Sector UCITS ETF | ESIH.DE | 9 | 2.79% |
| iShares SLI ETF (CH) | CSSLI.SW | 8 | 4.23% |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE) | EXV4.DE | 10 | 2.66% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | HLTH.L | 9 | 2.75% |
Funds with Lonza Group among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Core SPI(R) ETF (CH) | CHSPI.SW | 9 | 2.19% |
| iShares SMI ETF (CH) | CSSMI.SW | 9 | 2.77% |
| UBS ETF (CH) – SMI | SMICHA.SW | 9 | 2.64% |
| Xtrackers Switzerland UCITS ETF 1C | XSMC.SW | 9 | 2.77% |
| iShares MSCI Switzerland ETF | EWL | 8 | 2.84% |
| Amundi MSCI Europe SRI Climate Paris Aligned UCITS ETF DR (C) | MIVB.DE | 10 | 2.14% |
| iShares MSCI Europe Health Care Sector UCITS ETF | ESIH.DE | 9 | 2.79% |
| iShares SLI ETF (CH) | CSSLI.SW | 8 | 4.23% |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE) | EXV4.DE | 10 | 2.66% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | HLTH.L | 9 | 2.75% |
Funds with Lonza Group among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free